The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Expired CME Article

Molecular Mechanisms of Allergic Disease

Authors: Daniel Venarske, MD, Richard D. deShazo, MD

Abstract

Interaction of allergen with T-cells is associated with patterns of cytokine release by immunocompetent cells characterized as T-helper Th1 or Th2 T-immune responses. The Th2 pattern of inflammation induced by this cytokine release is associated with allergic diseases. The molecular mechanisms underlying allergic inflammation are the signals for immunoglobulin (Ig) E production and the activation of mast cells and eosinophils. Data suggesting that environmental exposure may play a role in the induction of the Th2 pattern of inflammation has led to the development of the “hygiene hypothesis.” Knowledge of the mechanisms of allergic inflammation has allowed the development of specific pharmacologic intervention to include 1) antibodies to IgE, 2) therapy tailored to regulate IgE production, and 3) modulation of cytokine release and function. Knowledge of the role of transcription factors in regulating gene activity as it relates to allergic inflammation is expanding and may also provide future targets for pharmacologic intervention.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Ninan TK, Russell G. Respiratory symptoms and atopy in Aberdeen schoolchildren: Evidence from two surveys 25 years apart. BMJ 1992; 304: 873–875.
 
2. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82: 233–252.
 
3. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma: United States, 1980–1999. MMWR Surveill Summ 2002; 51( 1): 1–13.
 
4. Liu AH. Endotoxin exposure in allergy and asthma: Reconciling a paradox. J Allergy Clin Immunol 2002; 109: 379–392.
 
5. Escoubet-Lozach L, Glass CK, Wasserman SI. The role of transcription factors in allergic inflammation. J Allergy Clin Immunol 2002; 110: 553–564.
 
6. Mullings RE, Wilson SJ, Puddicombe SM, et al. Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J Allergy Clin Immunol 2001; 108: 832–838.
 
7. Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313–319.
 
8. Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380: 630–633.
 
9. Bonilla FA. The role of IgE in allergy. UpToDate. Available at:http://www.uptodate.com/physicians/rheumatology_toclist.asp. Accessed September 17, 2003.
 
10. Bacharier LB, Geha RS. Molecular mechanisms of IgE regulation. J Allergy Clin Immunol 2000; 105: S547–S558.
 
11. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108( 2 Suppl): S65–S71.
 
12. Yamaguchi M, Sayama K, Yano K, et al. IgE enhances Fcε receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: Synergistic effect of IL-4 and IgE on human mast cell Fcε receptor I expression and mediator release. J Immunol 1999; 162: 5455–5465.
 
13. Boesiger J, Tsai M, Maurer M, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fcε receptor I expression. J Exp Med 1998; 188: 1135–1145.
 
14. Costa JJ, Galli SJ. Mast cells and basophils, in Rich RR, Fleisher TA, Schwartz BD, et al (eds): Clinical Immunology: Principles and Practice. St. Louis, Mosby-Year Book, 1996, vol 1, ed 1, pp 408–430.
 
15. Williams CM, Galli SJ. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 2000; 105: 847–859.
 
16. Rothenberg ME. Eosinophilia. N Engl J Med 1998; 338: 1592–1600.
 
17. Leung DY. Molecular basis of allergic diseases. Mol Genet Metab 1998; 63: 157–167.
 
18. Heath H, Qin S, Rao P, et al. Chemokine receptor usage by human eosinophils: The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997; 99: 178–184.
 
19. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720–1745.
 
20. Hamelmann E, Rolinck-Werninghaus C, Wahn U. From IgE to anti-IgE: Where do we stand? Allergy 2002; 57: 983–994.
 
21. Milgrom H, Fick RB Jr, Su JQ, et al; rhuMAb-E25 Study Group. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341: 1966–1973.
 
22. Barnes PJ. Anti-IgE therapy in asthma. UpToDate. Available at:http://www.uptodate.com/physicians/pulmonology_toclist.asp#Asthma. Accessed September 17, 2003.
 
23. Vercelli D, Jabara HH, Cunningham-Rundles C, et al. Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome. J Clin Invest 1990; 85: 1666–1671.
 
24. Zhang DH, Yang L, Cohn L, et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 1999; 11: 473–482.